sarpogrelate has been researched along with monocrotaline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, M; Kasukawa, R; Miyata, M; Ohira, H; Sasajima, T; Sato, Y | 1 |
| Hironaka, E; Hongo, M; Kinoshita, O; Mawatari, E; Okumura, N; Sakai, A; Terasawa, F; Ushiyama, Y; Yamazaki, A; Yazaki, Y | 1 |
2 other study(ies) available for sarpogrelate and monocrotaline
| Article | Year |
|---|---|
Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist.
Topics: Animals; Cell Division; Endothelium, Vascular; Hypertension, Pulmonary; Male; Monocrotaline; Proliferating Cell Nuclear Antigen; Pulmonary Alveoli; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Antagonists; Succinates | 2000 |
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.
Topics: Animals; Endothelium, Vascular; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; P-Selectin; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Survival Rate | 2003 |